Targeting multiple myeloma cells and their bone marrow microenvironment

Ann N Y Acad Sci. 2004 Dec;1028:390-9. doi: 10.1196/annals.1322.047.


Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies. Direct (cell-cell contact) and soluble (via cytokines) forms of interactions between MM cells and bone marrow stroma regulate growth, survival, and homing of MM cells. These interactions also play a critical role in angiogenesis and in myeloma bone disease. In recent years, several studies have established the biologic significance of cytokines in MM pathogenesis and delineated signaling cascades mediating their effects, providing the framework for related novel therapies targeting not only the MM cell, but also the bone marrow microenvironment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Arsenic Trioxide
  • Arsenicals / pharmacology
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / metabolism*
  • Boronic Acids / pharmacology
  • Bortezomib
  • Cell Adhesion
  • Cytokines / metabolism
  • Disease Progression
  • Disease-Free Survival
  • Humans
  • Ligands
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / therapy*
  • Neovascularization, Pathologic
  • Oxides / pharmacology
  • Protease Inhibitors / pharmacology
  • Pyrazines / pharmacology
  • Signal Transduction
  • Thalidomide / pharmacology


  • Antineoplastic Agents
  • Arsenicals
  • Boronic Acids
  • Cytokines
  • Ligands
  • Oxides
  • Protease Inhibitors
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Arsenic Trioxide